Protocol No.: GCT1184-02

A Phase 3 Randomized, Open-Label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator s Choice in Patients with Platinum Resistant Ovarian Cancer
Principal Investigator
Pfaendler, Krista
Phase
III
Age Group
Adult
Applicable Disease Site
Gynecologic Cancers
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Jill Stone, LPN
Research Specialist
Phone: +1 304-634-4417

View on ClinicalTrials.gov